Bristol-Myers Squibb Co. (BMY: Quote) and AstraZeneca PLC (AZN: Quote,AZN.L) on Monday announced the results of analyses showing that Onglyza 5 mg demonstrated improvements across key measures of blood sugar control compared to placebo in adult patients with type 2 diabetes at high risk for cardiovascular disease.
The results were from a pooled, post-hoc assessment of five, 24-week, Phase III studies encompassing 1,681 patients with type 2 diabetes and varying degrees of cardiovascular risk, characterized by the presence of known risk factors or a history of cardiovascular disease. Adverse events, serious adverse events, death, discontinuation and hypoglycemia were also evaluated by various patient sub-groups.
Onglyza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus in multiple clinical settings. Onglyza should not be used for the treatment of patients with type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in those settings.
When Onglyza was used in combination with a sulfonylurea or with insulin, the incidence of confirmed hypoglycemia was increased over that of placebo used in combination with a sulfonylurea or with insulin. Therefore, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia when used in combination with Onglyza.
| || |
| To receive FREE breaking news email alerts for Bristol-Myers Squibb Co. and others in your portfolio|
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org